Back to top
more

AngioDynamics (ANGO)

(Real Time Quote from BATS)

$7.32 USD

7.32
54,739

+0.33 (4.72%)

Updated Nov 6, 2024 10:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Add AngioDynamics to Your Portfolio

by Zacks Equity Research

AngioDynamics (ANGO) continues to benefit from strategic buyouts and strong product portfolio.

AngioDynamics (ANGO) Down 1.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis

by Zacks Equity Research

Quest Diagnostics' (DGX) new COVID-19 tests start adding to its Diagnostic information Services business sales.

AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.

AngioDynamics (ANGO) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 1.98%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AngioDynamics (ANGO) Q3 Earnings Expected to Decline

by Zacks Equity Research

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AngioDynamics (ANGO) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AngioDynamics (ANGO) Down 10.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to AngioDynamics Stock Now

by Zacks Equity Research

AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.

AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates

by Zacks Equity Research

AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.

AngioDynamics (ANGO) Beats Q2 Earnings Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 200.00% and -2.61%, respectively, for the quarter ended November 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AngioDynamics (ANGO) Q2 Earnings Expected to Decline

by Zacks Equity Research

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is AngioDynamics (ANGO) Up 0.9% Since Last Earnings Report?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AngioDynamics Boosts VIT Product Portfolio With New Buyout

by Zacks Equity Research

AngioDynamics (ANGO) is likely to see an expansion of its already existing VIT product portfolio with the buyout of Eximo Medical.

AngioDynamics (ANGO) Q1 Earnings Top, Revenues Lag Estimates

by Zacks Equity Research

AngioDynamics (ANGO) keeps fiscal 2020 revenue guidance intact, slashes EPS view.

Luminex Gets FDA Nod for ARIES MRSA Assay, Boosts Platform

by Zacks Equity Research

Luminex (LMNX) receives FDA clearance for the ARIES MRSA assay, which is likely to provide a boost to the company's ARIES platform.

AngioDynamics (ANGO) Q1 Earnings Beat Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 100.00% and -2.32%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AngioDynamics (ANGO) Q1 Earnings Expected to Decline

by Zacks Equity Research

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AngioDynamics (ANGO) Down 8.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates

by Zacks Equity Research

AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.

AngioDynamics (ANGO) Lags Q4 Earnings Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of -3.85% and 3.72%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics (ANGO) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AngioDynamics Divests NAMIC Portfolio to Medline Industries

by Zacks Equity Research

The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.

AngioDynamics IDE Application for NanoKnife Gets FDA Nod

by Zacks Equity Research

AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.

    Why Is AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report?

    by Zacks Equity Research

    AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.